Interview with Dr Jim Thomas and Karen Lackey
What role do Biologics play in the context of novel therapeutics? Jim: Biologics are a significant and growing portion of the arsenal of therapeutics used…
Learn more
Interview with Barbara Bachler-Konetzki about Evotec’s integrated antibody discovery capabilities
What were the limitations of previous hybridoma-based approaches? Although the development of the hybridoma technology was a landmark event, the methodology still faced the limitation…
Interview with RANDAL R. KETCHEM about the optimization of antibodies
How does optimization of antibodies improve development? Just – Evotec Biologics has developed a molecular optimisation platform for monoclonal antibodies to increase productivity, eliminate potential…
Just – Evotec Biologics Opens J.POD® 1 US in Redmond, Washington
J.POD® 1 US provides uniquely flexible cGMP manufacturing of kilograms to metric tons of biologics therapeutics J.POD facility expands Just – Evotec Biologics’ capabilities into commercial…
Evotec Accelerates Access to Biologic Therapeutics with Initiation of Manufacturing Facility in Toulouse
J.POD® 2 EU biomanufacturing will play a key role in addressing the need for therapeutic antibodies, including those related to infectious diseases such as COVID-19
G-CON Manufacturing and Just – Evotec Biologics Complete the Installation of Cleanroom PODs® for the First J.POD® Facility in North America
Just – Evotec Biologics’ Redmond, Washington site offers true meaning to “Facility of the Future” with flexible and podular manufacturing of clinical and commercial-stage biologics.…
Just – Evotec Biologics Expands Contract With Department of Defense For Manufacturing of Monoclonal Antibodies
Just – Evotec Biologics will manufacture anti-SARS-CoV-2 and other antibodies at its J.POD® manufacturing facility. Access to manufacturing capacity over a period of 7 years
Evotec Partners With Alloy Therapeutics to Expand its Antibody Discovery Platform
Evotec gains access to Alloy Therapeutics’ ATX-Gx™ humanised mouse platform for biologics discovery Partnership leverages complementary strengths of in silico, in vitro and in vivo…
Just – Evotec Biologics Receives Grant To Enable An Antibody Product For The Prevention Of COVID-19
Just – Evotec Biologics receives grant for COVID-19 monoclonal antibody optimisation and cell line development from the COVID-19 therapeutics accelerator Grant enables the optimisation of…
Biologics manufacturing without the big bioreactors
Producing therapeutic antibodies is expensive and difficult, but drug-makers have unprecedented flexibility in plant design through a new modular biologics manufacturing platform that streamlines the…
Just – Evotec Biologics to Produce Monoclonal Antibody Products Against COVID-19 for The Department of Defense
Just – Evotec Biologics to provide process development and manufacturing of monoclonal antibody
Just – Evotec Biologics Partners with ABL on Development of Broadly Neutralising Antibody Against HIV
Just – Evotec Biologics to provide process development required for phase I cGMP clinical manufacturing of broadly neutralising antibody against HIV